Evaluation of AR, AR-V7, and p160 family as biomarkers for prostate cancer: insights into the clinical significance and disease progression

Evaluation of AR, AR-V7, and p160 family as biomarkers for prostate cancer: insights into the clinical significance and disease progression

Purpose To assess the role of the p160 family, AR, and AR-V7 in different initial presentations of prostate cancer and their association with clinical endpoints related to tumor progression. Methods The study sample comprises 155 patients who underwent radical prostatectomy and 11 healthy peripheral...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology Vol. 150; no. 2; p. 70
Main Authors: Pimenta, Ruan, Malulf, Feres Camargo, Romão, Poliana, Caetano, Giovana Vilas Boas, da Silva, Karina Serafim, Ghazarian, Vitoria, dos Santos, Gabriel A., Guimarães, Vanessa, Silva, Iran Amorim, de Camargo, Juliana Alves, Recuero, Saulo, Melão, Bárbara V. Lima Aguiar, Antunes, Alberto Azoubel, Srougi, Miguel, Nahas, William, Leite, Katia R. M., Reis, Sabrina T.
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer Berlin Heidelberg 02-02-2024
Springer Nature B.V
Subjects:
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Biopsy
Cancer Research
Clinical Relevance
Disease Progression
Gene expression
Hematology
Humans
Internal Medicine
Male
Medicine
Medicine & Public Health
Metastases
Metastasis
Neoplasm Recurrence, Local - genetics
Oncology
Prostate cancer
Prostatectomy
Prostatic Neoplasms, Castration-Resistant - pathology
Protein Isoforms - metabolism
Receptors, Androgen - genetics
Statistical analysis
Steroid receptor coactivator 1
p160
Biomarkers
Prostate cancer
Androgen receptor
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To assess the role of the p160 family, AR, and AR-V7 in different initial presentations of prostate cancer and their association with clinical endpoints related to tumor progression. Methods The study sample comprises 155 patients who underwent radical prostatectomy and 11 healthy peripheral zone biopsies as the control group. Gene expression was quantified by qPCR from the tissue specimens. The statistical analysis investigated correlations between gene expression levels, associations with disease presence, and clinicopathological features. Additionally, ROC curves were applied for distinct PCa presentations, and time-to-event analysis was used for clinical endpoints. Results The AR-V7 diagnostic performance for any PCa yielded an AUC of 0.77 ( p  < 0.05). For locally advanced PCa, the AR-V7 AUC was 0.65 ( p  < 0.05). Moreover, the metastasis group had a higher expression of SRC-1 than the non-metastatic group ( p  < 0.05), showing a shorter time to metastasis in the over-expressed group ( p  = 0.005). Patients with disease recurrence had super-expression of AR levels ( p  < 0.0005), with a shorter time-to-recurrence in the super-expression group ( p  < 0.0001). Conclusion Upregulation of SRC-1 indicates a higher risk of progression to metastatic disease in a shorter period, which warrants further research to be applied as a clinical tool. Additionally, AR may be used as a predictor for PCa recurrence. Furthermore, AR-V7 may be helpful as a diagnostic tool for PCa and locally advanced cancer, comparable with other investigated tools.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1432-1335
0171-5216
1432-1335
DOI:10.1007/s00432-023-05598-x